A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma - PubMed (original) (raw)
. 1995 Sep 1;269(5228):1281-4.
doi: 10.1126/science.7652577.
Affiliations
- PMID: 7652577
- DOI: 10.1126/science.7652577
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
T Wölfel et al. Science. 1995.
Abstract
A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HLA-A2. 1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16INK4a, but not of p21 or of p27KIP1. The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a.
Similar articles
- TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
Kamesaki H, Nishizawa K, Michaud GY, Cossman J, Kiyono T. Kamesaki H, et al. J Immunol. 1998 Jan 15;160(2):770-7. J Immunol. 1998. PMID: 9551912 - Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C, Donovan J, Bhattacharya N, Stampfer M, Worland P, Slingerland J. Sandhu C, et al. Oncogene. 2000 Nov 9;19(47):5314-23. doi: 10.1038/sj.onc.1203908. Oncogene. 2000. PMID: 11103932 - The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2.
Reynisdóttir I, Massagué J. Reynisdóttir I, et al. Genes Dev. 1997 Feb 15;11(4):492-503. doi: 10.1101/gad.11.4.492. Genes Dev. 1997. PMID: 9042862
Cited by
- Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD. Lussier DM, et al. Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2102611118. doi: 10.1073/pnas.2102611118. Proc Natl Acad Sci U S A. 2021. PMID: 34099555 Free PMC article. - The role of neoantigens in response to immune checkpoint blockade.
Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. Riaz N, et al. Int Immunol. 2016 Aug;28(8):411-9. doi: 10.1093/intimm/dxw019. Epub 2016 Apr 5. Int Immunol. 2016. PMID: 27048318 Free PMC article. Review. - Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.
Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH. Evans RA, et al. JCI Insight. 2016 Sep 8;1(14):e88328. doi: 10.1172/jci.insight.88328. JCI Insight. 2016. PMID: 27642636 Free PMC article. - Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.
Omokoko T, Simon P, Türeci Ö, Sahin U. Omokoko T, et al. Oncoimmunology. 2015 Mar 19;4(7):e1005523. doi: 10.1080/2162402X.2015.1005523. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140230 Free PMC article. - Effector CD4 and CD8 T cells and their role in the tumor microenvironment.
Hadrup S, Donia M, Thor Straten P. Hadrup S, et al. Cancer Microenviron. 2013 Aug;6(2):123-33. doi: 10.1007/s12307-012-0127-6. Epub 2012 Dec 16. Cancer Microenviron. 2013. PMID: 23242673 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials